tachycardia tirzepatide Tirzepatide's Prediabetes and Hypertension Impact What evidence exists that tirzepatide

What stood out: CagriSema achieved 23.0% weight loss at 84 weeks (efficacy estimand) Tirzepatide achieved 25.5% On the treatment-regimen estimand, weight loss was 20.2% vs 23.6% Primary endpoint not met: CagriSema did not demonstrate non-inferiority vs tirzepatide on weight loss at 84 weeks Why this matters This is a reminder that in obesity pharmacotherapy, very effective and best-in-class are not the same conversation

Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a Phase III randomized controlled noninferiority trial

Read on for information distinguishing the differences between these new weight loss industry giants

This is when to consult your provider about holding at the previous dose for an additional four weeks before re-attempting the increase

Enhancing Metabolism: Certain medications in our arsenal are aimed at boosting your metabolism, which aids in increasing calorie expenditure and supports you in meeting your weight loss objectives